{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:29:19Z","timestamp":1793489359991,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012167","name":"National Science and Technology Infrastructure Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejphar.2026.179465","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:11:46Z","timestamp":1792771906000},"page":"179465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacodynamic evaluation of the novel vancomycin derivative LYSC98"],"prefix":"10.1016","volume":"1038","author":[{"given":"Xiu-Kun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Fang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-He","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ge","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong-Ying","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7505-7525","authenticated-orcid":false,"given":"Cong-Ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Fu","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.179465_bib2","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1128\/AAC.00760-10","article-title":"Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing","volume":"54","author":"Belley","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2026.179465_bib3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1021\/acsinfecdis.7b00258","article-title":"Developments in glycopeptide antibiotics","volume":"4","author":"Blaskovich","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejphar.2026.179465_bib4","doi-asserted-by":"crossref","first-page":"7795","DOI":"10.1128\/AAC.01732-15","article-title":"High prevalence of vanM in vancomycin-resistant Enterococcus faecium isolates from Shanghai, China","volume":"59","author":"Chen","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2026.179465_bib5","series-title":"CLSI Supplement M100","article-title":"Performance standards for antimicrobial susceptibility testing","year":"2023"},{"key":"10.1016\/j.ejphar.2026.179465_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jare.2019.10.005","article-title":"Vancomycin resistant Staphylococcus aureus infections: a review of case updating and clinical features","volume":"21","author":"Cong","year":"2020","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.ejphar.2026.179465_bib7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/bs.ampbs.2024.04.006","article-title":"Staphylococcus aureus response and adaptation to vancomycin","volume":"85","author":"Fait","year":"2024","journal-title":"Adv. Microb. Physiol."},{"key":"10.1016\/j.ejphar.2026.179465_bib8","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1128\/AAC.03172-14","article-title":"Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies","volume":"58","author":"Farrell","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2026.179465_bib9","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.179465_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s44280-025-00092-0","article-title":"Antimicrobial resistance profile of clinical isolates from hospitals across China: CHINET 2024 surveillance report","volume":"3","author":"Guo","year":"2025","journal-title":"One Health Adv"},{"key":"10.1016\/j.ejphar.2026.179465_bib11","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2147\/IDR.S399150","article-title":"Pharmacokinetics and pharmacodynamics of a novel Vancomycin derivative LYSC98 in a murine thigh infection model against Staphylococcus aureus","volume":"16","author":"He","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.ejphar.2026.179465_bib12","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","article-title":"Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus","volume":"49","author":"Higgins","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2026.179465_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00042-09","article-title":"Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications","volume":"23","author":"Howden","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejphar.2026.179465_bib14","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejphar.2026.179465_bib15","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2174\/0113816128415482250721112427","article-title":"Antimicrobial resistance: enzymes, proteins, and computational resources","volume":"32","author":"Mishra","year":"2026","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejphar.2026.179465_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s12088-024-01273-y","article-title":"Glycopeptides: insights towards resistance, clinical pharmacokinetics and pharmacodynamics","volume":"65","author":"Paritala","year":"2025","journal-title":"Indian J. Microbiol."},{"key":"10.1016\/j.ejphar.2026.179465_bib17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejphar.2026.179465_bib18","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO bacterial priority pathogens list 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejphar.2026.179465_bib19","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/pro.3819","article-title":"Molecular mechanisms of vancomycin resistance","volume":"29","author":"Stogios","year":"2020","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejphar.2026.179465_bib20","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s40265-015-0505-8","article-title":"Lipoglycopeptide antibacterial agents in gram-positive infections: a comparative review","volume":"75","author":"Van Bambeke","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2026.179465_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177423","article-title":"In vivo pharmacodynamic study of the novel polymyxin MRX-8","volume":"997","author":"Wang","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179465_bib22","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/jac\/dkad138","article-title":"In vivo pharmacodynamic study of contezolid acefosamil, a prodrug of contezolid for oral and intravenous administration","volume":"78","author":"Wang","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2026.179465_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkag036","article-title":"LYSC98 as a novel vancomycin-derived agent effective against antibiotic-resistant pathogens in tolerant state","volume":"81","author":"Xia","year":"2026","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2026.179465_bib24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jmii.2022.07.001","article-title":"The prevalence and molecular epidemiology of vancomycin-resistant Enterococcus (VRE) carriage in patients admitted to intensive care units in Beijing, China","volume":"56","author":"Yan","year":"2023","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.ejphar.2026.179465_bib25","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026989","article-title":"Approved glycopeptide antibacterial drugs: mechanism of action and resistance","volume":"6","author":"Zeng","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejphar.2026.179465_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2334-6-55","article-title":"Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases","volume":"6","author":"Zuluaga","year":"2006","journal-title":"BMC Infect. Dis."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926009477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926009477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:15:01Z","timestamp":1793488501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926009477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":25,"alternative-id":["S0014299926009477"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179465","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic evaluation of the novel vancomycin derivative LYSC98","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179465"}}